Drug Development Health Information Health IT 
Healthcare IT Today
JANUARY 8, 2024
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. Health Economics Outcomes Research (HEOR) will become more common in decentralized clinical trials (DCTs). AI’s influence also optimized drug manufacturing processes, enhancing efficiency, and reducing waste.
Lloyd Price
DECEMBER 2, 2024
Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! Subscribe Today!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. By the power vested in clinical research, the FDA now pronounces us patient and industry. You may now kiss the cancer survivor.
Lloyd Price
NOVEMBER 8, 2024
Focus on Digital Health and AI: European companies will invest in digital health startups and AI-driven solutions to improve patient outcomes and operational efficiency. Consolidation in Specific Segments: M&A activity will be concentrated in areas like telemedicine, medical devices, and health IT. Subscribe Today!
Lloyd Price
OCTOBER 28, 2024
Regulatory Hurdles: The stringent regulatory environment in healthcare can increase development costs and delay time to market, making it less attractive to investors. Patient Adoption: Patients may be hesitant to adopt new technologies, especially if they involve sharing personal health information or using AI-powered tools.
Healthcare IT Today
OCTOBER 1, 2022
John spoke to Dan Chavez of the Santa Cruz Health Information Organization about why including SDoH data makes patient identity more challenging but also more valuable to the clinicians and patients that SCHIO serves. Read more… One HIE’s Approach to Identity Management.
Lloyd Price
JANUARY 20, 2025
In the context of healthtech and digital health, it means a company initially targets consumers (B2C), builds a strong user base, and then leverages this consumer adoption to attract businesses (B2B), such as insurers, employers, or healthcare providers. Accelerate drug development: Speed up the clinical trial process and reduce costs.
Expert insights. Personalized for you.
89 
Let's personalize your content